CC BY-NC-ND 4.0 · AJP Rep 2018; 08(02): e85-e88
DOI: 10.1055/s-0038-1645879
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neonatal Thyrotoxicosis with Tricuspid Valve Regurgitation and Hydrops in a Preterm Infant Born to a Mother with Graves' Disease

Stefani Doucette
1   Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada
,
Anne Tierney
2   Section of Neonatology, Department of Pediatrics, University of Calgary, Cumming School of Medicine, Alberta, Canada
,
Anne Roggensack
3   Department of Obstetrics and Gynecology, University of Calgary, Cumming School of Medicine, Alberta, Canada
,
Kamran Yusuf
2   Section of Neonatology, Department of Pediatrics, University of Calgary, Cumming School of Medicine, Alberta, Canada
› Author Affiliations
Further Information

Publication History

18 October 2017

15 January 2018

Publication Date:
04 May 2018 (online)

Abstract

Neonatal hyperthyroidism is rare disorder due to the passage of thyroid receptor antibodies (TRBs) from the mother to the fetus. Neonatal thyrotoxicosis can present in several ways and if unrecognized, can be fatal. We present a preterm neonate who developed fetal hydrops and tricuspid regurgitation in utero. The mother had a history of treated Grave's disease. The infant responded to maternal treatment antenatally and postnatal anti-thyroid treatment, with resolution of both the tricuspid regurgitation and hydrops. To our knowledge, this is the first case report of tricuspid regurgitation associated with fetal and neonatal thyrotoxicosis. Our case also highlights the importance of obtaining a detailed and accurate history in a mother with previous Grave's disease, even if treated.

 
  • References

  • 1 Ogilvy-Stuart AL. Neonatal thyrotoxicosis. Neoreviews 2017; 18 (07) e422-e427
  • 2 Correia MF, Maria AT, Prado S, Limbert C. Neonatal thyrotoxicosis caused by maternal autoimmune hyperthyroidism. BMJ Case Rep 2015; 2015: bcr201409283
  • 3 Chan GW, Mandel SJ. Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab 2007; 3 (06) 470-478
  • 4 Park JH, Shong M, Lee JH, Choi SW, Jeong JO, Seong IW. Reversible severe tricuspid regurgitation with right heart failure associated with thyrotoxicosis. Thyroid 2006; 16 (08) 813-814
  • 5 Xenopoulos NP, Braden GA, Applegate RJ. Severe right heart failure in a patient with Grave's disease. Clin Cardiol 1996; 19 (11) 903-905
  • 6 Nakchbandi IA, Wirth JA, Inzucchi SE. Pulmonary hypertension caused by Graves' thyrotoxicosis: normal pulmonary hemodynamics restored by (131)I treatment. Chest 1999; 116 (05) 1483-1485
  • 7 Treadwell MC, Sherer DM, Sacks AJ, Ghezzi F, Romero R. Successful treatment of recurrent non-immune hydrops secondary to fetal hyperthyroidism. Obstet Gynecol 1996; 87 (5 Pt 2): 838-840
  • 8 Yanai N, Shveiky D. Fetal hydrops, associated with maternal propylthiouracil exposure, reversed by intrauterine therapy. Ultrasound Obstet Gynecol 2004; 23 (02) 198-201
  • 9 Bellini C, Hennekam RC. Non-immune hydrops fetalis: a short review of etiology and pathophysiology. Am J Med Genet A 2012; 158A (03) 597-605
  • 10 Ogilvy-Stuart AL. Neonatal thyroid disorders. Arch Dis Child Fetal Neonatal Ed 2002; 87 (03) F165-F171
  • 11 Van Vliet G, Polak M, Ritzén EM. Treating fetal thyroid and adrenal disorders through the mother. Nat Clin Pract Endocrinol Metab 2008; 4 (12) 675-682
  • 12 Stagnaro-Green A, Abalovich M, Alexander E. , et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21 (10) 1081-1125